LEADER 03981nam  22006855  450 
001 9910300237603321
005 20250710080229.0
010   $a1-4939-2047-2
024 7 $a10.1007/978-1-4939-2047-1
035   $a(CKB)3710000000375207
035   $a(EBL)1997938
035   $a(SSID)ssj0001465749
035   $a(PQKBManifestationID)11917435
035   $a(PQKBTitleCode)TC0001465749
035   $a(PQKBWorkID)11478348
035   $a(PQKB)11594980
035   $a(DE-He213)978-1-4939-2047-1
035   $a(MiAaPQ)EBC1997938
035   $a(PPN)184896231
035   $a(EXLCZ)993710000000375207
100   $a20150311d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aTargeted Therapies for Solid Tumors $eA Handbook for Moving Toward New Frontiers in Cancer Treatment /$fedited by Antonio Russo, Rafael Rosell, Christian Rolfo
205   $a1st ed. 2015.
210  1$aNew York, NY :$cSpringer New York :$cImprint: Humana,$d2015.
215   $a1 online resource (270 p.)
225 1 $aCurrent Clinical Pathology,$x2197-7828
300   $aDescription based upon print version of record.
311 08$a1-4939-2046-4 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aIntroduction -- Oncogene Addiction in Solid Tumors -- Pharmacology and Clinical Development of New Molecularly Targeted Agents -- Biomarkers as Prognostic, Predictive and Surrogate Endpoints -- Evaluation of Response in Malignant Tumors Treated with Targeted Agents -- Targeted Therapies for HER2-Positive Breast Cancer -- Role of PARP Inhibitors in Triple Negative Breast Cancer (TNBC) -- Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck -- Targeted Therapies for NSCLC -- Targeted Therapies for Gastric Cancer -- Targeted Therapies for Pancreatic Cancer -- Targeted Therapies in Hepatocellular Carcinoma -- Targeted Therapies for Colorectal Cancer -- Targeted Therapy in Gastrointestinal Stromal Tumors -- Targeted Therapies in Kidney Cancer -- Targeted Therapies in Melanoma -- Targeted Therapies for Prostate Cancer -- Targeted Therapies for Bone Metastases.
330   $aThis volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment provides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice.
410  0$aCurrent Clinical Pathology,$x2197-7828
606   $aPathology
606   $aOncology
606   $aCancer
606   $aPathology
606   $aOncology
606   $aCancer Biology
615  0$aPathology.
615  0$aOncology.
615  0$aCancer.
615 14$aPathology.
615 24$aOncology.
615 24$aCancer Biology.
676   $a616.992
702   $aRusso$b Antonio$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aRosell$b Rafael$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aRolfo$b Christian$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910300237603321
996   $aTargeted Therapies for Solid Tumors$91821468
997   $aUNINA